o
Expanded the international clinical acceptance of VBAS with studies being published or presented in China, Japan, Mexico and Taiwan.
●
Vycor acquired a portfolio of two US pending patents, and had an existing patent allowed, directed to novel neuro-navigation systems for neurosurgical access systems. This important patent purchase and allowance strengthens Vycor’s position in respect of its strategy to develop and commercialize VBAS devices designed to be fully integrated with selected Image Guided Systems (IGS). Vycor continues to build on its patent portfolio, and has filed an additional four new patents for VBAS-related technologies during 2015.
●
In March 2016 Vycor launched its VBASMini, two new smaller models of its TC range. The VBASMini was developed in close collaboration with a leading neurosurgeon who had identified a need to develop a much smaller VBAS than those currently available to allow for less invasive surgery yet still enable the use of instruments. The VBASMini is largest clear device available that can fit through a burr hole yet still provide a large enough working channel to be useful in neurosurgery, and was designed to overcome the limitations of carrying out work through the likes of an endoscopic sheath. The smaller size also enables minimally invasive approaches to areas where existing retractors are too potentially invasive, such as the ventricles.
Management Commentary
“We have been encouraged by the progress of NovaVision’s Internet-delivered therapies in the U.S. and the early positive reception in Europe,” said Peter Zachariou, CEO of Vycor Medical. “With the company’s limited resources we are focused initially on direct-to-patient website and social media marketing, before implementing the other marketing strategies. It takes an average of 10 weeks from contact to signing up a patient so the benefits of the new model take time to build.
“Vycor’s flat sales were a reflection of weak US sales in July and August which recovered in September and this recovery has continued into 2016. We have now launched our new VBASMini and have added 17 new sales reps in the US since Q3 2015 so are optimistic for the division.
“We have continued to reduce our operating loss before depreciation and amortization (or “Cash Burn”), which on a non-GAAP basis for the fourth quarter was $256,000 as compared to $459,000 for the fourth quarter of 2014, a reduction of 44%, and are focused on increasing revenues while maintaining our low costs, with the objective of continuing to decrease our Cash Burn”.
2015 Financial Results
Revenue totaled $1.1 million in the twelve months of 2015, as compared to $1.2 million for the prior year. Vycor Medical’s revenue in the twelve months of 2015 decreased by $8,000 to $885,000. This reflected weak sales in particular in the U.S. in July and August, which recovered in September and this recovery continued through December. Gross margin of 88% was achieved for Vycor in 2015 versus 87% in 2014.
NovaVision revenues in the twelve months of 2015 decreased by $104,000. Foreign exchange differences in Europe accounted for $26,000 of the revenue decrease, with the remainder mainly accounted for by the delayed launch of the new Internet-delivered therapy suite. New patient starts in the US for the second six months following the launch increased by 139% over the first six months of 2015 and by 57% over the second six months of 2014. Gross margin for NovaVision was 78% compared to 88% for 2014, which reflected a one-time write-off totalling $21,000 of inventory and components related to the replaced NovaVision legacy hardware delivery model.
Non-GAAP operating expenses in the twelve months of 2015 totaled $2.5 million as compared to $2.6 million in the prior year.
Non-GAAP net operating loss in the twelve months of 2015 was $1.5 million, unchanged from $1.5 million in the prior year.
Non-GAAP net loss in the twelve months of 2015 was $1.5 million, as compared to $1.7 million in the prior year.
Non-GAAP operating loss before depreciation and amortization (or “Cash Burn”) in the twelve months of 2015 was $1.3 million, as compared to $1.4 million in the prior year. This reflected some exceptional costs in the earlier part of the year. For the fourth quarter of 2015 the “Cash Burn” was $256,000 as compared to $459,000 for the fourth quarter of the prior year, a reduction of 44%.
VYCOR MEDICAL, INC.
| | |
| | |
| | | |
| | |
| | |
| | | |
| Revenue | | |
| Vycor Medical | $885,481 | $893,028 |
| NovaVision | $253,153 | $357,264 |
| | $1,138,634 | $1,250,292 |
| | | |
| Gross Profit | | |
| Vycor Medical | $777,953 | $780,424 |
| NovaVision | $196,563 | $313,568 |
| | $974,516 | $1,093,992 |
Reconciliation of Non-GAAP Information and Pro Forma Balance Sheet
Non-GAAP Reconciliation
Management uses certain non-GAAP financial measures (including non-GAAP operating expenses and non-GAAP net loss and loss per share), which exclude non-cash amortization of acquired intangible assets, non-cash stock-based compensation, one-time Offering costs and the change in value of derivative warrant liability. Management does not consider these costs in evaluating the continuing operations of the Company. Therefore, management calculates the non-GAAP financial measures provided in this earnings release excluding these costs and uses these non-GAAP financial measures to enable it to analyze further, and more consistently, the period-to-period financial performance of its core business operations. Management believes that providing investors with these non-GAAP measures gives them additional important information to enable them to assess, in the same way management assesses, the Company’s current and future continuing operations. There are limitations in using these non-GAAP financial measures because they are not prepared in accordance with GAAP and may be different from non-GAAP financial measures used by other companies. These non-GAAP financial measures should not be considered in isolation or as a substitute for GAAP financial measures. Investors and potential investors should consider non-GAAP financial measures only in conjunction with the Company’s consolidated financial statements prepared in accordance with GAAP. Set forth below are reconciliations of the non-GAAP financial measures to the comparable GAAP financial measures.
For the twelve months the Company reported Operating Expenses of $2,965,529 a net operating loss of $1,991,014 and a net loss of $2,083,643.
Vycor’s GAAP operating costs for the twelve months ended December 31, 2015 include non-cash amortization of acquired intangible assets ($234,466) and non-cash stock compensation charges ($274,502). Vycor’s other expenses included a change in derivative liability ($19,792) and a loss on foreign currency exchange ($63,711).
The Company is providing additional non-GAAP financial measures that exclude these charges and expenses, and reconciliation of GAAP to non-GAAP results is provided in the tables included in this release.
Operating Expenses for the twelve months ended December 31, 2015 were $2,456,562, non-GAAP net operating loss was $1,482,046, and non-GAAP net loss was $1,529,756.
About Vycor Medical, Inc.
Vycor Medical (OTCQB: VYCO) is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions. The company has a portfolio of FDA cleared medical solutions that are changing and improving lives every day. The company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.
For the latest information on the company, including media and other coverage, and to learn more, please go online at www.vycormedical.com, www.vycorvbas.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words "forecast", "anticipate", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Vycor Medical's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Vycor Medical’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Vycor Medical herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Vycor Medical disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
VYCOR MEDICAL, INC.
Consolidated Statements of Comprehensive Loss
(unaudited)
| | For the year ended December 31, |
| | | |
| | | |
| Revenue | $1,138,634 | $1,250,292 |
| Cost of Goods Sold | 164,118 | 156,300 |
| Gross Profit | 974,516 | 1,093,992 |
| | | |
| Operating expenses: | | |
| Research and development | 71,512 | 69,114 |
| Depreciation and Amortization | 360,334 | 368,605 |
| General and administrative | 2,533,684 | 3,388,421 |
| Total Operating expenses | 2,965,530 | 3,826,140 |
| Operating loss | (1,991,014) | (2,732,148) |
| | | |
| Other income (expense) | | |
| Interest expense: Related Party | - | (80,093) |
| Interest expense: Other | (47,710) | (50,627) |
| Gain (loss) on foreign currency exchange | (63,711) | (105,685) |
| Loss on extinguishment of debt | - | (682,039) |
| Loss on extension of warrants | - | (146,488) |
| Change in fair value derivative liability | 19,792 | (252,633) |
| Total Other Income (expense) | (91,629) | (1,317,565) |
| | | |
| Loss Before Credit for Income Taxes | (2,082,643) | (4,049,713) |
| Credit for income taxes | - | - |
| Net Loss | (2,082,643) | (4,049,713) |
| Preferred stock dividends | (167,777) | - |
| Net Loss available to common shareholders | (2,250,420) | (4,049,713) |
| Comprehensive Loss | | |
| Foreign Currency Translation Adjustment | (64,959) | (112,318) |
| Comprehensive Loss | (2,315,379) | (4,162,031) |
| | | |
| Net Loss Per Share | | |
| Basic and diluted | $(0.21) | $(0.39) |
| | | |
| Weighted Average Number of Shares Outstanding – Basic and Diluted | 10,839,335 | 10,270,657 |
| | Twelve months ended December 31, |
| | | |
| | | |
| | | |
| GAAP Operating Expenses | $2,965,529 | $3,826,140 |
| | | |
| Non-cash amortization of acquired intangible assets | (234,466) | (234,467) |
| Non-cash stock-based compensation | (274,502) | (376,662) |
| Offering Costs | - | (581,702) |
| | | |
| Total Non-GAAP Operating Expense Adjustments | (508,968) | (1,192,831) |
| | | |
| | | |
| Non-GAAP Operating Expenses | $2,456,561 | $2,633,309 |
| | | |
| GAAP Operating Loss | $(1,991,014) | $(2,732,148) |
| | | |
| Non-GAAP Operating Expense Adjustments, as above | 508,968 | 1,192,831 |
| | | |
| | | |
| Non-GAAP Operating Loss | $(1,482,046) | $(1,539,317) |
| | | |
| GAAP Net Loss | $(2,082,643) | $(4,049,712) |
| | | |
| Non-GAAP Operating Expense Adjustments, as above | 508,968 | 1,192,831 |
| Change in value of derivative liability | (19,792) | 252,633 |
| Gain (loss) on foreign currency exchange | 63,711 | 105,685 |
| Loss on extinguishment of debt | - | 682,039 |
| Loss on extension of warrants | - | 146,488 |
| | | |
| Non-GAAP Net Loss | $(1,529,756) | $(1,670,036) |
| | | |
| Non-GAAP Loss Per Share | | |
| Basic and diluted | $(0.14) | $(0.16) |
| | | |
| Weighted Average Number of Shares Outstanding | 10,839,335 | 10,270,657 |
| | | |
| Non-GAAP Operating Loss Before Depreciation And Amortization | $(1,356,180) | $(1,405,178) |
Vycor Medical, Inc Contacts:
6401 Congress Avenue
Suite 140
Boca Raton, FL. 33487
(561) 558-2020
info@vycormedical.com
